LIMN.NASDAQIris Parent Holding CORP
SCHEDULE 13D: Valetudo Therapeutics and CEO Chris Kim Disclose 23.7% Stake in Newly Formed Liminatus Pharma Post-Merger
Sentiment:
Beneficial Ownership Disclosure
Valetudo Therapeutics LLC and its CEO, Chris Kim, have filed a Schedule 13D, revealing a significant 23.7% beneficial ownership in Liminatus Pharma, Inc. following the recent business combination.
Summary
- Valetudo Therapeutics LLC and Chris Kim jointly filed a Schedule 13D, reporting beneficial ownership of 6,169,406 shares of Liminatus Pharma, Inc. Common Stock.
- This ownership represents 23.7% of the total 26,014,633 shares of Common Stock outstanding after the Business Combination.
- The shares were acquired on April 30, 2025, as part of the Business Combination, where Liminatus Pharma, LLC merged into Liminatus Pharma, Inc. (formerly Iris Parent Holding Corp.) and Iris Acquisition Corp. also merged into Liminatus Pharma, Inc.
- Valetudo Therapeutics LLC received these shares in exchange for its membership interests in Liminatus Pharma, LLC.
- Chris Kim, who serves as CEO and a director of Liminatus Pharma, Inc., also holds voting and dispositive power over the shares owned by Valetudo Therapeutics LLC.
- In connection with the Business Combination, the Reporting Persons entered into an Amended and Restated Registration Rights Agreement, granting them registration rights for their shares.
- Valetudo Therapeutics LLC also entered into a Lock-Up Agreement, restricting the transfer of its shares for specified periods: one-third for six months, one-third for twelve months, and one-third for twenty-four months from the Closing Date, subject to certain price-based or corporate event exceptions.
Sentiment
Score: 7
Explanation: The document is a standard regulatory filing disclosing beneficial ownership post-merger. The significant insider stake is generally positive for alignment, while the lock-up is a common and expected feature in such transactions. No negative operational or financial news is present.
Positives
- The successful consummation of the Business Combination signifies a major corporate milestone for Liminatus Pharma, Inc.
- A substantial 23.7% ownership stake by Valetudo Therapeutics LLC and its CEO, Chris Kim, aligns the interests of key insiders with the company's performance.
- The granting of registration rights provides a clear pathway for future liquidity for the Reporting Persons, allowing for potential orderly sales of shares.
Negatives
- The Lock-Up Agreement imposes significant restrictions on the transferability of the Reporting Persons' shares, limiting their immediate liquidity for periods ranging from six months to two years.
Risks
- The lock-up agreement restricts the ability of Valetudo Therapeutics LLC to sell a significant portion of its shares for up to 24 months, potentially impacting its financial flexibility.
- Upon the expiration of the lock-up periods or achievement of release conditions (e.g., $12.00 share price), future sales by the Reporting Persons could introduce selling pressure on the stock.
- The value of the investment is subject to general market conditions and the specific financial and operational performance of Liminatus Pharma, Inc.
Future Outlook
The Reporting Persons intend to continuously review their investment in Liminatus Pharma, Inc. They may consider acquiring additional securities, retaining or selling existing holdings, engaging in discussions with management, the Board of Directors, or other shareholders, and making recommendations regarding the company's capitalization, ownership structure, board composition, potential business combinations, or operational performance.
Management Comments
- "Chris Kim serves as CEO and a director of the Issuer and has voting and dispositive power over the shares held by Valetudo Therapeutics LLC."
- "The Reporting Persons acquired the shares reported herein for investment purposes."
- "The Reporting Persons intend to review their investment in the Issuer on a continuing basis."
Industry Context
NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer and Director | NA | Chris Kim | April 30, 2025 | Confirmation of role in the newly combined entity, Liminatus Pharma, Inc., following the Business Combination. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Name Change and Corporate Structure | The Issuer (formerly Iris Parent Holding Corp.) filed an amended and restated certificate of incorporation, changing its name to 'Liminatus Pharma, Inc.' as part of the Business Combination. | April 30, 2025 | Formalizes the new corporate identity and structure post-merger, reflecting the integration of Liminatus Pharma, LLC. |
| Shareholder Rights Agreement | An Amended and Restated Registration Rights Agreement was entered into, granting the Reporting Persons specific rights to register their shares for resale. | April 30, 2025 | Provides a mechanism for future liquidity for significant shareholders, potentially influencing future share supply. |
| Share Transfer Restrictions | A Lock-Up Agreement was entered into by Valetudo Therapeutics LLC, restricting the transfer of its beneficially owned shares for periods of 6, 12, and 24 months, subject to certain conditions. | April 30, 2025 | Limits immediate selling pressure from a major shareholder, potentially contributing to short-term share price stability, but also restricts liquidity for the Reporting Person. |
Related Party Transactions
- The Business Combination itself involved related entities: Liminatus Pharma, LLC (in which Valetudo Therapeutics LLC held membership interests) merged into the Issuer.
- Chris Kim serves as CEO of Valetudo Therapeutics LLC and also as CEO and a director of Liminatus Pharma, Inc., establishing a direct related-party relationship.
- The issuance of 6,169,406 shares of Common Stock to Valetudo Therapeutics LLC was a direct result of the exchange of its membership interests in Liminatus Pharma, LLC during the merger.
- The Amended and Restated Registration Rights Agreement and the Lock-Up Agreement were entered into between the Issuer and the Reporting Persons/Valetudo Therapeutics LLC, governing the rights and restrictions related to their significant shareholding.
Stakeholder Impact
- **Shareholders**: The filing confirms a substantial insider ownership (23.7%) by Valetudo Therapeutics LLC and Chris Kim, which can be viewed positively as it aligns their interests with long-term company performance. The lock-up agreement provides a degree of stability by preventing immediate large-scale sales by these significant holders, while registration rights offer a future path for their liquidity.
- **Management/Board**: Chris Kim's dual role as CEO and director of Liminatus Pharma, Inc., combined with his significant beneficial ownership, grants him considerable influence over the company's strategic direction and corporate activities.
Next Steps
- Reporting Persons may acquire additional securities of Liminatus Pharma, Inc. in the open market or privately negotiated transactions.
- Reporting Persons may retain or sell all or a portion of their current holdings.
- Chris Kim, in his capacity as CEO and director, may influence the corporate activities of Liminatus Pharma, Inc.
- Reporting Persons may engage in communications with Liminatus Pharma's management and Board of Directors.
- Reporting Persons may discuss with other shareholders or third parties regarding Liminatus Pharma and their investment.
- Reporting Persons may propose changes to Liminatus Pharma's capitalization, ownership structure, board composition, or suggest improvements to financial/operational performance.
Key Dates
| Date | Description |
|---|---|
| November 30, 2022 | Date of the original Business Combination Agreement. |
| April 30, 2025 | Closing Date of the Business Combination; Liminatus Pharma, Inc. completed the merger, filed an amended and restated certificate of incorporation, changed its name, issued 6,169,406 shares to Valetudo Therapeutics LLC, and Reporting Persons entered into the Amended and Restated Registration Rights Agreement and Lock-Up Agreement. |
| May 6, 2025 | Date of Form 8-K filing by the Issuer with the SEC, incorporating the Registration Rights Agreement and Lock-Up Agreement. |
| May 7, 2025 | Date of execution of the Joint Filing Agreement and signature of the Schedule 13D by the Reporting Persons. |
Keywords
Liminatus Pharma, Valetudo Therapeutics, Chris Kim, Schedule 13D, Beneficial Ownership, Business Combination, Merger, Common Stock, Lock-Up Agreement, Registration Rights, Corporate Governance, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.